News
Does olaparib improve overall survival in patients with recurrent ovarian cancer and BRCA mutation?
Olaparib, a poly(ADP-ribose) polymerase (PARP) enzyme inhibitor, in tablet form is indicated, among other things, for the maintenance treatment of adult patients with platinum-sensitive recurrent high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who respond (complete or partial response) to platinum-based chemotherapy. Its efficacy in this indication in terms of prolonging progression-free survival and overall survival was addressed by the phase III study presented below.
Trazodone in the Treatment of Depressive Disorder – A Case Study
Presented by MUDr. Sylva Racková, Ph.D.
Psychiatric Clinic, Plzeň
Hydrotherapy in the Treatment of Non-Healing Wounds
For the treatment of wounds, it is crucial how they are managed during the cleaning and granulation…
International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with…
COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care…
Invasive Pulmonary Aspergillosis – A Common Accompanying Infection in Patients with Severe or Critical Course of COVID-19
Findings based on a literature review conducted and published in September 2020 show the occurrence…
Trifluridine/Tipiracil in the 3rd Line Treatment of mCRC − Case Study
The following case study describes the treatment of a patient with metastatic colorectal cancer…
Atectura® and Enerzair®: new fixed dual and triple combination in the treatment of bronchial asthma
In mid-2020, the European Commission approved two new fixed combinations of drugs by Novartis for…
Recent Advances in Physiotherapy for Hemophiliacs
Physiotherapy specifically focuses on movement and the movement potential of the individual, with…
Turoctocog Alfa Pegol with Extended Half-Life in the Treatment of Severe Hemophilia A
GlycoPEGylated recombinant factor VIII (rFVIII) with an extended half-life, turoctocog alfa pegol,…
Conferences
News from the world of medicine
All conferences
Popular this week
- BENIGN DERMATOSIS OF PENIS
- Target blood pressure values in heart failure
- Could Artificial Intelligence Help with Emergency Department Triage in the Future?
- A Cap Instead of a Brain Implant?
- AI Can Provide Surgeons with Valuable Data and Real-Time Feedback